Fosun International : JOINT ANNOUNCEMENT - THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF SHANGHAI HENLIUS ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE - LISTING OF SHANGHAI HENLIUS AND COMMENCEMENT OF DEALINGS IN THE SHANGHAI HENLIUS H SHARES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the ''U.S. Securities Act''). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America or any jurisdiction other than Hong Kong.

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

上 海 復 星 醫 藥 （ 集 團 ） 股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

JOINT ANNOUNCEMENT

THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF SHANGHAI HENLIUS

ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE

LISTING OF SHANGHAI HENLIUS AND COMMENCEMENT OF DEALINGS

IN THE SHANGHAI HENLIUS H SHARES

The boards of directors of Fosun Pharma and Fosun International are pleased to announce that following the completion of the Global Offering, listing of Shanghai Henlius on the Main Board of the Hong Kong Stock Exchange took place on 25 September 2019 and dealings in the Shanghai Henlius H Shares on the Main Board of the Hong Kong Stock Exchange commenced at 9:00 a.m. on 25 September 2019.

1. INTRODUCTION

Fosun Pharma refers to its announcements dated 27 September 2018, 13 December 2018, 5 July 2019, 21 August 2019, 25August 2019, 10 September 2019, 12 September 2019 and 18 September 2019 (the ''Fosun Pharma Announcements'') and the circular to its shareholders dated 11

- 1 -

October 2018 (the ''Fosun Pharma Circular'') relating to the Proposed Spin-off and Listing. The Proposed Spin-off and Listing were approved by Fosun Pharma's shareholders at the 2018 First Extraordinary General Meeting held on 27 November 2018.

Fosun International refers to its announcements dated 27 September 2018, 13 December 2018, 5 July 2019, 21 August 2019, 25 August 2019, 10 September 2019, 12 September 2019 and 18 September 2019 (the ''Fosun International Announcements'') relating to, among other things, the Proposed Spin-off and Listing.

Unless the context otherwise requires, terms defined in the Fosun Pharma Announcements, the Fosun Pharma Circular and the Fosun International Announcements shall have the same meanings as those used in this announcement.

2. LISTING OF SHANGHAI HENLIUS AND COMMENCEMENT OF DEALINGS IN THE SHANGHAI HENLIUS H SHARES

The Hong Kong Stock Exchange has granted the listing of, and permission to deal in, the Shanghai Henlius H Shares on the Main Board of the Hong Kong Stock Exchange.

Following the completion of the Global Offering, (i) listing of Shanghai Henlius on the Main Board of the Hong Kong Stock Exchange took place on 25 September 2019 and (ii) dealings in the Shanghai Henlius H Shares on the Main Board of the Hong Kong Stock Exchange commenced at 9:00 a.m. on 25 September 2019. The Shanghai Henlius H Shares are traded in board lots of 100 Shanghai Henlius H Shares each and the stock code is 2696.

The spin-off and separate listing of Shanghai Henlius from Fosun Pharma and Fosun International promotes the achievement of further developments by Shanghai Henlius and the enhancement of the overall value of Fosun Pharma and Fosun International.

By order of the board	By order of the board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*	Fosun International Limited
Chen Qiyu	Guo Guangchang
Chairman	Chairman
25 September 2019

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetang, Mr. Wang Can and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.

• For identification purposes only

- 2 -